Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study

Am J Ophthalmol. 2017 Aug:180:110-116. doi: 10.1016/j.ajo.2017.05.024. Epub 2017 Jun 1.

Abstract

Purpose: To explore the distribution of nonperfusion area (NPA) in eyes with diabetic macular edema (DME) and its relationship with the severity of DME.

Design: Prospective, observational case series.

Methods: Forty eyes of 29 patients with treatment-naïve DME who participated in the DAVE study (NCT01552408) were included. Ultra-widefield fluorescein angiography images were sent to the Doheny Image Reading Center, where they were montaged and corrected using stereographic projection to adjust for peripheral distortion. Two experienced, independent/masked certified graders manually segmented the NPA and the total visible retinal area (TRA), and computed the NPA and TRA in square millimeters (mm2). The ischemic index (ISI) was calculated. The distributions of NPA and ISI within different retinal zones were correlated with the severity of DME.

Results: In 40 eyes with treatment-naïve DME (mean age, 55.8 years) visual acuity (VA) (mean 59.6 EDTRS letters) was correlated with central macular thickness (CMT) (mean 536.9 μm, R = -0.418, P = .008) and macular volume (MV) (mean 11.9 mm3, R = -0.449, P = .004). The NPA and ISI among the different retinal zones were significantly different (NPA: P < .001; ISI: P = .005). The NPA and ISI in the midperiphery were negatively associated with CMT (NPA: P = .04; ISI: P = .02). However, the global NPA and ISI for the entire retina were not associated with CMT or MV (P > .05).

Conclusion: In eyes with DME, the ISI increases with increasing distance from the fovea. The severity of DME does not appear to correlate with global NPA and ISI.

Publication types

  • Observational Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use
  • Capillaries / pathology
  • Diabetic Retinopathy / diagnosis*
  • Diabetic Retinopathy / drug therapy
  • Diabetic Retinopathy / physiopathology
  • Female
  • Fluorescein Angiography*
  • Humans
  • Intravitreal Injections
  • Ischemia / diagnosis*
  • Ischemia / physiopathology
  • Macular Edema / diagnosis*
  • Macular Edema / drug therapy
  • Macular Edema / physiopathology
  • Male
  • Middle Aged
  • Prospective Studies
  • Ranibizumab / therapeutic use
  • Retinal Vessels / pathology*
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Ranibizumab